Junshi Biosciences Archives | Page 14 of 14

Home / Posts tagged Junshi Biosciences (Page 14)

Junshi Biosciences Announces Acceptance of a Supplemental NDA in China for Toripalimab in Advanced Nasopharyngeal Carcinoma

SHANGHAI, China, April 30 (Korea Bizwire) — Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, today announced that the China National Medical Products Administration (NMPA) has accepted a supplemental New Drug Application (sNDA) for toripalimab as a treatment for patients with recurrent/metastatic nasopharyngeal carcinoma [...]

Junshi Biosciences Announces Full-Year 2019 Financial Results and Business Updates

SHANGHAI, March 30 (Korea Bizwire) — Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced its audited consolidated annual results of the Company and its subsidiaries for the full-year ended December 31, 2019. Financial Highlights (IFRS): Total revenue was RMB775 million, mainly due to [...]

Junshi Biosciences Receives Orphan Drug Designation from the U.S. FDA for Toripalimab in Combination with Pfizer’s Axitinib for the Treatment of Mucosal Melanoma

SHANGHAI, China, March 30 (Korea Bizwire) — Junshi Biosciences (HKEX: 1877) today announced that the U.S. Food and Drug Administration (FDA) has recently granted Orphan Drug Designation (ODD) for toripalimab in combination with Pfizer’s axitinib for the treatment of patients with mucosal melanoma. Toripalimab is an anti-PD-1 monoclonal antibody developed by Junshi. Toripalimab received its [...]

Junshi Biosciences Announces Co-Development Agreement with IMCAS to Advance Neutralizing Antibodies as Potential Novel Treatment for COVID-19

SHANGHAI, China, March 20 (Korea Bizwire) — Junshi Biosciences (HKEK: 1877) announced that it has recently signed a collaboration agreement with the Institute of Microbiology of the Chinese Academy of Sciences (IMCAS) to jointly develop neutralizing antibodies, a potential novel treatment for COVID-19. Junshi Biosciences and IMCAS have been working together to explore innovative treatments [...]

Junshi Biosciences Reports Key 2019 Financial Results

SHANGHAI, China, March 2 (Korea Bizwire) — Shanghai Junshi Biosciences Co., Ltd. (“the Company,” HKEX: 1877), an innovation-driven biopharmaceutical company dedicated to the discovery and development of innovative drugs with clinical research and commercialization on a global scale, today reported key financial results for the year 2019. The disclosure of the unaudited results is in [...]